RADIATION THERAPY ONCOLOGY GROUP

罗切斯特大学（UR）的研究人员继续发挥主要作用， 在国家一级设计和制定RTOG协议中的作用 以及为病例登记和RTOG临床的开展做出贡献 各级试验：I期、II期、III期和癌症控制 问题研究 研究战略副主席和主席办公室 议定书委员会的两个机构都设在辐射司， 罗切斯特大学癌症中心（URCC）的肿瘤学（DRO）。 这 促进研发和运营小组设计活动的开展， 将这些想法纳入工作协议， 优先研究。 这些目标是在一个双重的 时尚. 首先，作为主要研究主题， 包括定时给药和分次给药方案、超分次给药 放射增敏剂、放射防护剂、大视野和半身照射， 高LET照射，放疗和化疗的最佳时机， 热疗和其他放射治疗的创新方法 数学建模 其次，对不同的解剖部位进行评价 以确定哪种方法最适合特定的研究。 这些 包括脑神经胶质瘤、头颈癌、肺癌、前列腺癌 癌症、结肠直肠癌、妇科肿瘤和血液肿瘤 恶性肿瘤 UR研究人员对半身体特别感兴趣 放射治疗隐匿性转移。 超分割正在兴起 作为领先的研究概念，在一些网站和UR 研究人员正在积极地将这两个概念结合起来， 创新研究。 另一个特别感兴趣的领域是使用 辐射防护剂和辐射增敏剂，我们独特的研究 实验室支持系统起着至关重要的作用。 半体概念的使用 与辐射防护剂和辐射增敏剂已经开发出在我们的 目前，该机构正在进行测试。 其他关注领域 包括结肠直肠癌和前列腺癌， 最近的研究，以及辐射毒理学和病理学， 重新设计恶性血液病的治疗方案 乌拉圭回合是一个 案例的主要贡献者和RTOG信誉良好的受资助成员 自10年前成立以来，

The University of Rochester (UR) investigators continue to play a major role in the design and development of RTOG protocols on the national level as well as contributing to the case accession and conduct of RTOG Clinical Trials at all levels: Phase I, Phase II, Phase III and Cancer Control Studies. The offices of Vice Chairman for Research Strategies and Chairman of the Protocol Committee are both located within the Division of Radiation Oncology (DRO) at the University of Rochester Cancer Center (URCC). This facilitates development of the design activities of the RTOG and smooth incorporation of these ideas into working protocols, allowing for prioritizing of studies. These ends are accomplished in a two-fold fashion. Firstly, studies are reviewed as major research themes which include time dose and fractionation schedules, hyperfractionation, radiosensitizers, radioprotectors, large field and hemi-body irradiation, high LET irradiation, optimal timing of radiation therapy and chemotherapy, hyperthermia and other innovative approaches in radiation therapy with mathematical modeling. Secondly, different anatomical sites are evaluated to determine which is best suited for specific research studies. These include brain gliomas, head and neck cancers, lung cancers, prostate cancer, colo-rectal cancers, gynecologic tumors and hematologic malignancies. The UR investigators are particularly interested in hemibody irradiation for treating occult metastases. Hyperfractionation is emerging as the leading research concept in a number of sites and the UR investigators are actively combining these two concepts in unique and innovative studies. Another area of particular interest is the use of radioprotectors and radiosensitizers in which our unique research laboratory support system plays a vital role. Use of the hemi-body concept with the radioprotectors and radiosensitizers has been developed at our institution and is currently being tested. Additional areas of interest include colorectal and prostate cancer, areas which the UR has proposed studies recently, as well as radiation toxicology and pathology and redesigning protocols for hematologic malignancies. The UR has been a major contributor of cases and a funded member in good standing of the RTOG since its inception a decade ago.